CN108379495A - Galangal rhizome extract is preparing the purposes in preventing and/or treating nonalcoholic fatty liver preparation - Google Patents
Galangal rhizome extract is preparing the purposes in preventing and/or treating nonalcoholic fatty liver preparation Download PDFInfo
- Publication number
- CN108379495A CN108379495A CN201810501185.2A CN201810501185A CN108379495A CN 108379495 A CN108379495 A CN 108379495A CN 201810501185 A CN201810501185 A CN 201810501185A CN 108379495 A CN108379495 A CN 108379495A
- Authority
- CN
- China
- Prior art keywords
- galangal rhizome
- rhizome extract
- fatty liver
- nonalcoholic fatty
- galangal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000062241 Kaempferia galanga Species 0.000 title claims abstract description 57
- 235000013421 Kaempferia galanga Nutrition 0.000 title claims abstract description 57
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 claims abstract description 16
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims abstract description 14
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 claims abstract description 8
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 claims abstract description 8
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims abstract description 7
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000008777 kaempferol Nutrition 0.000 claims abstract description 7
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003944 flavone Natural products 0.000 claims abstract description 4
- 235000011949 flavones Nutrition 0.000 claims abstract description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 8
- LYISDADPVOHJBJ-UHFFFAOYSA-N 3-methylgalangin Chemical compound O1C2=CC(O)=CC(O)=C2C(=O)C(OC)=C1C1=CC=CC=C1 LYISDADPVOHJBJ-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- LFTCAWISZXBLJD-UHFFFAOYSA-N galangin-3-O-methyl ether Natural products O1C2=CC(O)=CC(O)=C2CC(OC)=C1C1=CC=CC=C1 LFTCAWISZXBLJD-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000004809 thin layer chromatography Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 2
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 abstract description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 2
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 abstract description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- -1 chromocor compound Chemical class 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000013298 Alpinia <beetle> Species 0.000 description 1
- 244000141218 Alpinia officinarum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to biotechnologies, are related to galangal rhizome extract and are preparing the purposes in preventing and/or treating nonalcoholic fatty liver preparation.General flavone content is 99wt% or more in the galangal rhizome extract, the galangal rhizome extract contains Galangin 67wt% 85wt%, 3 O methyl ether 7wt% 21wt% of Galangin, 4 ' O methyl ether 2wt% 13wt% of Kaempferol, summation are no more than 100%.The triglycerides, cholesterol, ALT, AST that the galangal rhizome extract of the present invention can reduce nonalcoholic fatty liver mouse are horizontal, have the function of increasing high density lipoprotein, reduce low-density lipoprotein.
Description
Technical field
The invention belongs to biotechnologies, prevent and/or treat non-preparing more particularly, to galangal rhizome extract
Purposes in alcohol fatty hepar.
Background technology
Non-alcoholic fatty liver disease (Non-alcoholic fatty liverdisease, NAFLD) is worldwide
Diagnosis constantly rise, be considered as one of most common liver diseases in western countries, account for about the 20%- of total population
30%.It is increasingly becoming the increasingly severe chronic liver disease problem in China simultaneously, incidence is about 15%.Nonalcoholic fatty liver
Hepatopathy, heavy drinking is clearly damaged with other caused by the factor of liver except referring to becomes pathology with diffusivity liver cell fat
The clinical syndrome of feature, including simple fatty liver, nonalcoholic fatty liver disease and its relevant hepatic sclerosis and liver cell
Cancer.In recent years, due to the change of improvement of living standard, life style and dietary structure and relatively lagging behind for precautionary measures
Deng NAFLD incidence rises year by year, becomes worldwide health problem.The progress of NAFLD is one and inflammation, oxidative stress, from
It bites, er stress and the relevant complex process of insulin resistance, there is no the drug of effectively treatment nonalcoholic fatty liver at present,
Chinese medicine, natural drug are the rarities in China, and material base is natural products, for Western medicine, have structure-rich, activity
Unique, the features such as side effect is low, action target spot is various, be the important sources of China's original new drug, and selection exploitation is a kind of in Chinese medicine
The drug of the lower prevention nonalcoholic fatty liver of safe and effective and toxic side effect, has extremely vast market prospect,
And good social and economic benefit can be created.
Galangal (Alpinia officinarum Hance) is Zingiber (Zingiberaceae) Alpinia plants, alias
Small galingal, current chart ginger, are a kind of plant resources of dietotherapeutic, often cook seasoning use in Guangdong and country in Southeast Asia, are one
Kind medical and edible dual purpose plant, rhizome are used as medicine, and have warming stomach for dispelling cold, promoting qi circulation and relieving pain effect.Galangal has the cultivation of centuries in China
Training and medicinal history contain a large amount of chromocor compound and Diphenylheptane compound in galangal.Modern pharmacological studies have shown that
Galangal and extract have antitumor, antibacterial, antiviral, anti-obesity, anti-gastric-ulcer and a protective effects on gastric mucosa, but about
Galangal rhizome extract prevention nonalcoholic fatty liver there is no pertinent literature to report at present.
Invention content
The object of the present invention is to provide a kind of new application of galangal rhizome extract, specially galangal rhizome extract is being prepared in advance
Purposes in anti-and/or treatment nonalcoholic fatty liver preparation.
To achieve the goals above, a kind of galangal rhizome extract of present invention offer is preparing prevention and/or is treating non-alcohol
Property fat hepar in purposes, general flavone content is 99wt% or more in the galangal rhizome extract, the galangal extraction
Object contains Galangin 67wt%-85wt%, Galangin -3-O- methyl ether the 7wt%-21wt%,-O- methyl ethers of Kaempferol -4 '
2wt%-13wt%, summation are no more than 100%.
In the present invention, each component content is preferably measured using high-efficient liquid phase technique, specifically, is surveyed with reference to following documents
It is fixed：Zhao Xiao Di, Chen Xiaohui, Geng Lulu etc., HPLC methods measure the content of 3 kinds of flavones ingredients in galangal simultaneously.Pharmaceutical Analysis
Magazine, 2009,29 (12)：2036-2039.
Galangal rhizome extract of the present invention is preferably made by method comprising the following steps：By galangal rhizome powder
It is broken, methyl tertiary butyl ether(MTBE) is added and carries out homogenate extraction, filters to obtain the dregs of a decoction, the dregs of a decoction add ethyl acetate to extract, and recycle acetic acid second
Ester extract obtains galangal rhizome extract medicinal extract, and medicinal extract is by column chromatography for separation, petroleum ether-ethyl acetate gradient elution, thin layer
Chromatography monitoring, merging contain Galangin, Galangin -3-O- methyl ether %, and the fraction of-O- methyl ethers of Kaempferol -4 ' removes fraction
In petroleum ether-ethyl acetate solvent, then through ethyl alcohol recrystallization, the galangal rhizome extract is made.
Specifically, homogenate extraction can carry out twice.Ethyl acetate is added to extract and can carry out at normal temperatures.The methyl
The dosage of tertbutyl ether and ethyl acetate can be the 4-6 mass times of object to be extracted.
According to the present invention, petroleum ether-ethyl acetate gradient elution preferably uses volume ratio 10: 1,8: 1,5: 1,3: 1,1: 1
Petroleum ether-ethyl acetate gradient eluent.
According to the present invention, the column chromatography is preferably polyamide column chromatography.
According to a kind of specific implementation mode of the present invention, the galangal rhizome extract is made by following steps：By galangal
Rhizome crushes, and adds 4-6 times of methyl tert-butyl ether solvent, flash extracter to extract 2 times, filters to obtain the dregs of a decoction.The dregs of a decoction add 4-6 times again
Ethyl acetate extracts 2 times, obtains acetic acid ethyl acetate extract, and recycling ethyl acetate obtains galangal rhizome extract medicinal extract, and medicinal extract passes through polyamides
Amine column chromatography for separation, the petroleum ether-ethyl acetate gradient elution for being 10: 1,8: 1,5: 1,3: 1,1: 1 with volume ratio, thin-layer chromatography
Monitoring, merging contain Galangin, Galangin -3-O- methyl ether %, the fraction of-O- methyl ethers of Kaempferol -4 ', fraction recycling oil
Ether-ethyl acetate solvent, then can be obtained with ethyl alcohol recrystallization.
In the present invention, the preparation both can be drug, or food, such as health food.
The drug may include one or more pharmaceutically acceptable carriers.As used herein, term " pharmaceutically may be used
The carrier of receiving " refers to the excipient and/or adjuvant for promoting the active component of the present invention to be processed into preparation that can be medicinal.For
The suitable excipient of the present invention includes the filler of such as carbohydrate (for example, lactose, sucrose, mannitol, D-sorbite)；Fiber
Plain derivative；Magnesium sulfate；Calcium phosphate (for example, tricalcium phosphate, calcium monohydrogen phosphate)；Such as gelatinized corn starch is (for example, cornstarch, wheat
Starch, rice starch, potato starch), the adhesive of gel, tragacanth or polyvinylpyrrolidone.It can be used for the present invention
Suitable adjuvant include throttling agent and lubricant, such as talcum, silica, stearic acid or derivatives thereof (for example, magnesium stearate),
And/or polyethylene glycol.
It can be by any ideal administration route, including in oral, local, intramuscular, intraperitoneal, subcutaneous, tumor or vein
Approach gives the preparation of the drug.In the present invention, the dosage form of the drug can be the dosage form of the various conventional suitables in this field,
Including but not limited to tablet, capsule, granule, pill, oral solution.
Other features and advantages of the present invention will be described in detail in subsequent specific embodiment part.
Description of the drawings
Exemplary embodiment of the invention is described in more detail in conjunction with the accompanying drawings, it is of the invention above-mentioned and its
Its purpose, feature and advantage will be apparent.
Fig. 1 shows the Normal group liver structure observed under light microscopic.
Fig. 2 shows the model group liver structures observed under light microscopic.
Fig. 3-5 shows the galangal rhizome extract low dose group, galangal rhizome extract middle dose group, height observed under light microscopic
Rhizoma Alpiniae Officinarum extract high dose group liver structure.
Fig. 6 shows the positive drug group liver structure observed under light microscopic.
Specific implementation mode
The preferred embodiment of the present invention is described in more detail below.Although the following describe the preferred implementations of the present invention
Mode, however, it is to be appreciated that may be realized in various forms the present invention without should be limited by embodiments set forth herein.
The galangal rhizome extract further illustrated the present invention below by way of specific effect experiment is small to nonalcoholic fatty liver
The intervention and therapeutic effect of mouse.
1, drug
Given the test agent：The galangal rhizome extract of the present invention is made by following preparation method：Galangal rhizome is crushed,
Add 5 times of methyl tert-butyl ether solvent, flash extracter to extract 2 times, filters to obtain the dregs of a decoction.The dregs of a decoction add 5 times of ethyl acetate extractions 2 again
It is secondary, acetic acid ethyl acetate extract is obtained, recycling ethyl acetate obtains galangal rhizome extract medicinal extract, and medicinal extract is detached by polyamide column chromatography,
The petroleum ether-ethyl acetate gradient elution for being 10: 1,8: 1,5: 1,3: 1,1: 1 with volume ratio, thin-layer chromatography monitoring, merging contain
Galangin, Galangin -3-O- methyl ether %, the fraction of-O- methyl ethers of Kaempferol -4 ', it is molten that fraction recycles petroleum ether-ethyl acetate
Agent, then can be obtained with ethyl alcohol recrystallization.
Positive control drug：Fenofibrate, French Li Bofuni drugmakers production.
2, animal：SPF grades of Kunming mouse models, 8 week old, weight 20-22g, male；In being tested by the Central China University of Science and Technology
The heart provides.
3, experimental method
60 SPF grades of male mouse of kunming are randomly divided into 6 groups, respectively：1. Normal group, 2. positive drug group is (non-
Nobert 10mg/kg), 3. galangal rhizome extract high dose group (200mg/kg), 4. galangal rhizome extract middle dose group (100mg/
Kg) 5. galangal rhizome extract low dose group (50mg/kg), 6. model group, every group 10.After adaptable fed 1 week, except normal right
Outer according to group, remaining 5 groups with high lipid food (autogamy：Basal feed 73%, lard 25%, cholesterol 2%), continuously it is fed with 16
Week recorded weekly mouse food ration and mouse weight from feeding high lipid food first week, and mouse is raised in clean animal room
It supports, room temperature：22 ± 2 DEG C, humidity：Ventilation in 30~70%, 20 minutes is primary, each 12 hours of light and shade.Galangal rhizome extract, fenofibrate
Spy dissolved with 0.5%CMC-Na, the high, medium and low dose concentration of galangal rhizome extract be respectively 50mg/kg, 100mg/kg,
200mg/kg, gavage, once a day, continuous 16 weeks；Blank control group and the corresponding 0.5%CMC- of hyperlipidemia model group intragastric administration on mice
Na solution.It is deprived of food but not water 12h after the last administration, weighs in, eye socket takes blood, and liver is won in rapid dissection.From left lobe of liver phase
The hepatic tissue that one piece of about 1.5cm × 1.5cm × 1.5cm sizes are taken with position is completely soaked and is fixed in 10% paraformaldehyde liquid,
It is dyed for subsequent slice HE.HE stained slices are in 200 times of light microscopic observations.
As shown in Figure 1, light is under the microscope, Normal group liver structural integrity, liver cell arrangement is radial, and liver cell is big
Small form is normal, has no the abnormalities such as hepatic steatosis, oedema.As shown in Fig. 2, most of liver cell under model group hepatic tissue mirror
There is apparent fat to become, cell becomes larger, and fat drips are larger.As in Figure 3-5, galangal rhizome extract is from low dosage to high low dosage
Group, liver cell fat become degree and mitigate successively, and apparent dosage correlation is presented.It is thin that Fig. 5 can be seen that galangal high dose group liver
Born of the same parents' fat becomes quantity and significantly reduces, and almost uniform in size, form is normal.As shown in fig. 6, fenofibrate group murine liver tissue pathology
Histology is similar to Normal group, no abnormality seen lesion.To sum up, it can be seen that galangal rhizome extract is to nonalcoholic fatty liver
With significant improvement.
The blood biochemistry index such as blood fat, transaminase are detected according to biochemistry detection kit operating instruction.
Experimental data is tentatively arranged with office excel, with mean+SD/standard error (mean ± SD/SEM)
It indicates, analyzed using 17.0 statistical softwares of SPSS, experimental result is all made ofIt indicates, comparison among groups use single factor test variance
Analysis.
The results are shown in Table 1.
Influence of 1 galangal rhizome extract of table to nonalcoholic fatty liver mouse liver function
As it can be seen from table 1 the galangal rhizome extract of the present invention can reduce the glycerine three of nonalcoholic fatty liver mouse
Ester, cholesterol, ALT, AST are horizontal, have the function of increasing high density lipoprotein, reduce low-density lipoprotein.And galangal
High dose group has and the comparable effect of positive drug.
Various embodiments of the present invention are described above, above description is exemplary, and non-exclusive, and
It is not limited to disclosed each embodiment.Without departing from the scope and spirit of illustrated each embodiment, for this skill
Many modifications and changes will be apparent from for the those of ordinary skill in art field.
Claims (9)
1. galangal rhizome extract is preparing the purposes in preventing and/or treating nonalcoholic fatty liver preparation, which is characterized in that institute
It is 99wt% or more to state general flavone content in galangal rhizome extract, and the galangal rhizome extract contains Galangin 67wt%-
85wt%, Galangin -3-O- methyl ether the 7wt%-21wt%,-O- methyl ether 2wt%-13wt% of Kaempferol -4 ', summation do not surpass
Cross 100%.
2. galangal rhizome extract according to claim 1 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that each component content is measured using high-efficient liquid phase technique.
3. galangal rhizome extract according to claim 1 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that the galangal rhizome extract by method comprising the following steps be made：By galangal rhizome powder
It is broken, methyl tertiary butyl ether(MTBE) is added and carries out homogenate extraction, filters to obtain the dregs of a decoction, the dregs of a decoction add ethyl acetate to extract, and recycle acetic acid second
Ester extract obtains galangal rhizome extract medicinal extract, and medicinal extract is by column chromatography for separation, petroleum ether-ethyl acetate gradient elution, thin layer
Chromatography monitoring, merging contain Galangin, Galangin -3-O- methyl ether %, and the fraction of-O- methyl ethers of Kaempferol -4 ' removes fraction
In petroleum ether-ethyl acetate solvent, then through ethyl alcohol recrystallization, the galangal rhizome extract is made.
4. galangal rhizome extract according to claim 3 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that homogenate extraction carry out twice.
5. galangal rhizome extract according to claim 3 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that petroleum ether-ethyl acetate gradient elution use volume ratio 10: 1,8: 1,5: 1,3: 1,1: 1 oil
Ether-ethyl acetate gradient liquid.
6. galangal rhizome extract according to claim 3 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that the column chromatography be polyamide column chromatography.
7. galangal rhizome extract according to claim 1 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that the preparation includes drug and/or health food.
8. galangal rhizome extract according to claim 7 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that the drug includes one or more pharmaceutically acceptable carriers.
9. galangal rhizome extract according to claim 7 is in preparing prevention and/or treatment nonalcoholic fatty liver preparation
Purposes, which is characterized in that the dosage form of the drug be selected from tablet, capsule, granule, pill, oral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810501185.2A CN108379495B (en) | 2018-05-23 | 2018-05-23 | Application of galangal extract in preparation of preparation for preventing and/or treating non-alcoholic fatty liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810501185.2A CN108379495B (en) | 2018-05-23 | 2018-05-23 | Application of galangal extract in preparation of preparation for preventing and/or treating non-alcoholic fatty liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108379495A true CN108379495A (en) | 2018-08-10 |
| CN108379495B CN108379495B (en) | 2021-09-24 |
Family
ID=63071037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810501185.2A Active CN108379495B (en) | 2018-05-23 | 2018-05-23 | Application of galangal extract in preparation of preparation for preventing and/or treating non-alcoholic fatty liver disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108379495B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108686152A (en) * | 2018-08-13 | 2018-10-23 | 武汉轻工大学 | Application of the galangal rhizome extract in preparing the drug and/or health products for the treatment of pneumonia and/or pulmonary fibrosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879613A (en) * | 2005-06-16 | 2006-12-20 | 广州汉方现代中药研究开发有限公司 | Medicine containing galangin and preparation method thereof |
| CN101637503A (en) * | 2009-08-19 | 2010-02-03 | 大连中植环境生物科技有限公司 | Total flavonoids of broussonetia papyrifera extract and preparation method and application thereof |
| CN103479635A (en) * | 2013-08-01 | 2014-01-01 | 中国人民解放军第三〇二医院 | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof |
| CN104906483A (en) * | 2015-05-26 | 2015-09-16 | 南京泽朗医药科技有限公司 | Technology for extracting galangal total flavonoids |
-
2018
- 2018-05-23 CN CN201810501185.2A patent/CN108379495B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879613A (en) * | 2005-06-16 | 2006-12-20 | 广州汉方现代中药研究开发有限公司 | Medicine containing galangin and preparation method thereof |
| CN101637503A (en) * | 2009-08-19 | 2010-02-03 | 大连中植环境生物科技有限公司 | Total flavonoids of broussonetia papyrifera extract and preparation method and application thereof |
| CN103479635A (en) * | 2013-08-01 | 2014-01-01 | 中国人民解放军第三〇二医院 | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof |
| CN104906483A (en) * | 2015-05-26 | 2015-09-16 | 南京泽朗医药科技有限公司 | Technology for extracting galangal total flavonoids |
Non-Patent Citations (2)
| Title |
|---|
| 国家药典委员会: "《中华人民共和国药典临床用药须知》", 30 September 2017, 中国医药科技出版社 * |
| 李洪福，等: "高良姜化学成分及药理活性的研究", 《中国实验方剂学杂质》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108686152A (en) * | 2018-08-13 | 2018-10-23 | 武汉轻工大学 | Application of the galangal rhizome extract in preparing the drug and/or health products for the treatment of pneumonia and/or pulmonary fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108379495B (en) | 2021-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Bioactive platycodins from Platycodonis Radix: Phytochemistry, pharmacological activities, toxicology and pharmacokinetics | |
| Guo et al. | Traditional uses, phytochemistry, pharmacology and toxicology of the genus Cimicifuga: A review | |
| Fu et al. | Aconitum carmichaelii Debeaux: a systematic review on traditional use, and the chemical structures and pharmacological properties of polysaccharides and phenolic compounds in the roots | |
| CN106065023B (en) | Condensed tannin class compound, its medical composition and its use | |
| CN101829138B (en) | Composition for strengthening immune regulation function in human body and applications thereof | |
| Zheng et al. | Research advances in lotus leaf as Chinese dietary herbal medicine | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN101590086B (en) | Fructus akebiae extract, preparation and application thereof | |
| CN1330670C (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| Gong et al. | Traditional uses, phytochemistry, pharmacology, applications, and quality control of Gastrodia elata Blume: A comprehensive review | |
| CN107551001B (en) | A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method | |
| CN108379495A (en) | Galangal rhizome extract is preparing the purposes in preventing and/or treating nonalcoholic fatty liver preparation | |
| CN103815397B (en) | Downgrade food compositions of blood pressure, blood fat and blood sugar and preparation method thereof | |
| KR101491493B1 (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
| CN108815463A (en) | Natural drug, preparation method and application with cancer prevention effect | |
| CN101011457A (en) | Traditional Chinese medicine composition with immunological enhancement function | |
| Gou et al. | Traditional uses, phytochemistry, and pharmacology of Persicaria orientalis (L.) Spach-A review | |
| CN106822095A (en) | A kind of medicine and its application in pharmacy for preventing and treating fatty liver and obesity | |
| CN101664423A (en) | Hypoglycemic active part of osmanthus fragrans, preparation method and application thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN105168300A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| KR101647506B1 (en) | Detoxifying methods for extracts of Coptidis Rhizoma, detoxified herbal extracts manufactured by the same, and composition comprising for preventing and treating a respiratory organ disease comprising the herbal extracts | |
| CN1539844A (en) | 2,3,5,4'-tetrahydroxy diphenyl ethylene-2-1-beta-D-glucoside | |
| CN104473992B (en) | A kind of Radix Platycodonis extract and the new application in medicine and health products are prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |